NCEL — NewcelX Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1783036 ·
Switzerland
Last close
$3.15
Market Cap
$16.96M
52W High
$5.12
52W Low
$1.83
ADV30
56,793
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 11,445,000 | 2,201,000 | 4,195,000 |
| Jun 2025 | — | — | — | — | 459,252 | 297,893 | 15,487,801 |
| Dec 2024 | — | — | — | — | 903,000 | 650,000 | 8,899,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-84,891,000
Inventory
—
Receivables
$55,559
ST Investments
—
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -2,474,000 | -8,300,000 | 11,445,000 | 4,195,000 | — | -2,766,000 |
| Dec 2024 | 0 | -1,797,000 | -7,197,000 | 903,000 | 8,899,000 | — | -1,066,000 |
| Dec 2023 | 0 | -3,015,000 | -3,332,000 | 2,203,725 | 3,352,211 | — | -3,444,000 |
| Dec 2022 | 0 | -6,245,743 | -6,446,652 | 3,543,984 | 3,451,476 | — | -5,674,234 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| XCUR | EXICURE, INC. | $17.04M | $2.67 | — |
| MDCX | Medicus Pharma Ltd. | $16.54M | $0.29 | — |
| LEXX | Lexaria Bioscience Corp. | $16.49M | $0.67 | — |
| HCWB | HCW Biologics Inc. | $17.64M | $2.62 | — |
| SCNX | Scienture Holdings, Inc. | $16.25M | $0.40 | — |
News headlines (Yahoo Finance, 1h cache)
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
2026-05-01 18:00 · Yahoo
Despite NewcelX's Pullback, Insiders Still Gained ₪136k
2026-05-01 10:36 · Yahoo
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
2026-04-30 12:15 · Yahoo
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
2026-04-20 11:37 · Yahoo
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
2026-04-01 11:21 · Yahoo
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
2026-03-09 11:00 · Yahoo
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
2026-02-12 12:00 · Yahoo
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
2026-01-29 12:00 · Yahoo
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
2026-01-12 12:00 · Yahoo
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
2026-01-05 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.